Physician profile
Michael E Allen
NPI 1386737922
$2,315.27
in general payments reported to CMS, 2019-2025
18 companies · $15.08 in 2025
The $15.08 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $808 · 2023: $243 · 2024: $177 · 2025: $15.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $823.10 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $549.54 | 2021-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $474.99 | 2021-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $116.36 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $87.19 | 2021 | |
| Indivior INC. | $34.73 | 2021-2022 | |
| Shield Therapeutics INC | $24.51 | 2022 | |
| Abbvie INC. | $23.26 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.52 | 2022 | |
| Janssen Biotech, INC. | $21.05 | 2021 | |
| Abbott Laboratories | $20.56 | 2021 | |
| Neos Therapeutics, Lp | $20.22 | 2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $17.81 | 2021 | |
| Galt Pharmaceuticals, LLC | $17.62 | 2023 | Orphengesic Forte |
| Janssen Pharmaceuticals, INC | $17.60 | 2023 | Spravato |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $16.77 | 2021 | |
| Tris Pharma INC | $16.26 | 2022 | |
| Noven Therapeutics, LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.